Treatment of clozapine‐associated obesity and diabetes with exenatide in adults with schizophrenia: <scp>A</scp> randomized controlled trial ( <scp>CODEX</scp> )

Siskind, Dan; Russell, Anthony; Gamble, Clare; Winckel, Karl; Mayfield, Karla; Hollingworth, Samantha; J. Hickman, Ingrid; Siskind, Victor; Kisely, Steve

doi:10.1111/dom.13167

Public

Treatment of clozapine‐associated obesity and diabetes with exenatide in adults with schizophrenia: A randomized controlled trial ( CODEX )

Published in Diabetes Obesity and Metabolism • Nov 30, 2017

Authors:

Dan Siskind

Anthony Russell

Clare Gamble

Abstract

Clozapine causes obesity and type 2 diabetes (T2DM). Glucagon‐like peptide‐1 (GLP‐1) receptor agonists (e.g. exenatide) can counter clozapine‐associated GLP‐1 dysregulation in animals, and may be beneficial in people on clozapine. This randomized, controlled, open‐label, pilot trial evaluated weekly...

Subject

Medicine

Exenatide

Clozapine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!